ING Group’s Acadia Pharmaceuticals ACAD Stock Holding History

ING Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-456,177	Closed	-$6.97M	–	763
2018 Q2	$6.97M	Buy	+456,177	New	+$8.13M	0.13%	95
2017 Q2	–	Sell	-11,300	Closed	-$388K	–	826
2017 Q1	$388K	Sell	11,300 -19,665	-64%	-$694K	0.01%	474
2016 Q4	$891K	Sell	30,965 -4,000	-11%	-$106K	0.02%	333
2016 Q3	$1.14M	Buy	+34,965	New	+$1.19M	0.01%	274
2013 Q4	–	Sell	-41,000	Closed	-$1.13M	–	687
2013 Q3	$1.13M	Buy	+41,000	New	+$857K	0.01%	548

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

ING Group's ACAD Position: Q3 2018 in Review

ING Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2018, closing a stake of 456,177 shares — an estimated $6.97M sold.

ING Group first reported a position in ACAD in Q3 2013 and held it in 5 quarters. The position peaked at $6.97M in Q2 2018. 184 funds tracked by Wall St. Rank hold ACAD as of Q3 2018.

ING Group reported no remaining Acadia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
ING Group sold 456,177 Acadia Pharmaceuticals shares in Q3 2018, an estimated $6.97M.
ING Group first reported a position in Acadia Pharmaceuticals in Q3 2013 and held it in 5 quarters.
ING Group's Acadia Pharmaceuticals position peaked at $6.97M in Q2 2018.
184 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2018.

Based on ING Group's 13F filing for Q3 2018, filed 6 Nov 2018.